Bristol Myers Earnings Are a ‘Tale of 2 Trends’ as Guidance Falls Short. The Stock Is Falling
Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price ...
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...
FiercePharma17h
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...
BioPharma Dive11h
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...
Bristol Myers expects to deliver additional ~$2B in cost savings by 2027-end
Squibb is expanding its existing strategic productivity initiative to include approximately $2B in additional annualized ...
devdiscourse9h
Health Sector Shake-Ups: From Bristol Myers' Forecasts to Global Aid Impacts
Recent health news includes Bristol Myers' projected revenue dip due to generic competition and cost cuts, Trump's tariffs ...
Eli Lilly, Bristol Myers Squibb, Peloton: Market Minute
Yahoo Finance Anchor Josh Lipton recaps the top stories on Wall Street as part of today's Market Minute. US stocks (^DJI, ...
These Stocks Are Moving the Most Today: Qualcomm, Lilly, Skyworks, Ford, Honeywell, Strategy, Roblox, Bristol Myers, Amazon, and More
Qualcomm trades lower after earnings, Eli Lilly stock rises on upbeat guidance, Skyworks says its share of the business to ...